Avicanna Sponsors THC Dose-Finding Trial with University of Calgary — Avicanna Inc.

Event summary

Avicanna is sponsoring a Phase I randomized, double-blinded, placebo-controlled, dose-finding clinical trial led by the University of Calgary’s Cumming School of Medicine.
The trial will enroll 24 healthy adult participants to test single oral doses of THC at 6 mg, 9 mg, and 15 mg, along with placebo.
The trial utilizes Avicanna’s proprietary AVCN319301b THC capsules, which use the company’s Solid Self-Emulsifying Drug Delivery System (SEDDs) technology.
Primary endpoints focus on psychometric assessments of anxiety and subjective response, with secondary endpoints including mood, intoxication, cardiovascular parameters, and pharmacokinetic profiling.

The big picture

Avicanna’s sponsorship of this clinical trial underscores its strategic focus on advancing cannabinoid-based pharmaceuticals through rigorous scientific research. The trial’s outcomes could validate the company’s proprietary delivery technology and support its broader pipeline of indication-specific cannabinoid candidates. This initiative aligns with the growing trend of leveraging clinical data to differentiate products in the competitive medical cannabis market.

What we're watching

Clinical Validation: How the trial results will impact the therapeutic window of oral THC and the interindividual variability in response.
Technology Adoption: Whether Avicanna’s SEDDs technology will demonstrate superior absorption and consistency compared to traditional cannabis formulations.
Pipeline Progression: The pace at which Avicanna can advance its pharmaceutical pipeline through additional investigator-led research.